Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MicroGeneSys' VaxSyn HIV therapeutic vaccine

Executive Summary

The "disapproval notification period" for the Phase III trial of the gp160 vaccine has been extended for an additional six months following President Clinton's signing of the FY 1994 Defense Department appropriations bill on Nov. 11. The language agreed to in the funding bill's conference report, which passed both chambers Nov. 10, implements an amendment offered by Rep. Waxman (D-Calif.) Sept. 30 ("The Pink Sheet" Oct. 11, T&G-9). MicroGeneSys says Nov. 12 that it is "concerned that the recent congressional action will likely delay Phase III trials of gp160 in the United States.".
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS023647

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel